An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties

Biomaterials

Volumn 34, Issue 8, 2013, Pages 2077-2086

  Bae, Sang Mun ^a   Kim, Jong Ho ^b   Chung, Seung Woo ^c   Byun, Youngro ^c   Kim, Sang Yoon ^d,e   Lee, Byung Heon ^a   Kim, In San ^a,e   Park, Rang Woon ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

^c Seoul National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

Author keywords

Angiogenesis; ApoPep 1 conjugated LMWH taurocholate; Apoptosis; Homing peptide; In vivo imaging

Indexed keywords

ANGIOGENESIS; ANGIOGENESIS INHIBITORS; ANTI-ANGIOGENIC ACTIVITY; ANTIANGIOGENIC; ANTICOAGULANT PROPERTIES; ANTITUMOR EFFECT; ANTITUMOR PROPERTY; APOPEP-1-CONJUGATED LMWH-TAUROCHOLATE; APOPTOTIC; APOPTOTIC CELLS; BREAST CARCINOMAS; CANCER MODELS; CIRCULATION TIME; CLINICAL TRIAL; HISTOLOGICAL EVALUATION; HOMING PEPTIDE; IN-VIVO; IN-VIVO IMAGING; LOW MOLECULAR WEIGHT; LOW-MOLECULAR WEIGHT HEPARINS; TAUROCHOLATE; TUMOR CELLS; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SITE; TUMOR TISSUES; TUMOR VESSELS; VESSEL FORMATION;

DRUG PRODUCTS; ENDOTHELIAL CELLS; MAMMALS; MOLECULAR WEIGHT; PEPTIDES; POLYSACCHARIDES; TUMORS;

CELL DEATH;

ANGIOGENESIS INHIBITOR; APOPEP 1; CD31 ANTIGEN; HEPARIN DERIVATIVE; LHT 7; LOW MOLECULAR WEIGHT HEPARIN; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CELL ASSAY; CELL HOMING; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; ENDOTHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PROTEIN BINDING; TAUROCHOLIC ACID; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84871527298     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.11.020     Document Type: Article

References (34)

1. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
2. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13:159-167.
3. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:149-153.
4. Folkman J., Langer R., Linhardt R.J., Haudenschild C., Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983, 221:719-725.
5. Smorenburg S.M., van Noorden C.J.F. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001, 53:93-105.
6. Jaques L.B. Heparins: anionic polyelectrolyte drugs. Pharmacol Rev 1980, 31:100-166.
7. Hirsh J. Heparin. N Engl J Med 1991, 324:1565-1579.
8. Lee A.Y. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 2002, 28:137-140.
9. Verheul H., Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485.
10. Robert C., Faivre S., Raymond E., Armand J.P., Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors. Ann Intern Med 2005, 143:313-314.
11. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002, 2:521-528.
12. Stevenson J.L., Choi S.H., Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selection inhibition, not antithrombotic activity. Clin Cancer Res 2005, 11:7003-7011.
13. Pisano C., Aulicino C., Vesci L., Casu B., Naggi A., Torri G., et al. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005, 15:1-6.
14. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 2001, 98:3352-3357.
15. Collen A., Smorenburg S.M., Peters E., Lupu F., Koolwijk P., van Noorden C., et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000, 60:6196-6200.
16. Bose S., Tuunainen I., Parry M., Medina O.P., Mancini G., Kinnunen P.K. Binding of cationic liposomes to apoptotic cells. Anal Biochem 2004, 331:385-394.
17. Wang K., Purushotham S., Lee J.Y., Na M.H., Park H., Oh S.J., et al. In vivo imaging of tumor apoptosis using histone H1-targeting peptide. J Control Release 2010, 148:283-291.
18. Familian A., Zwart B., Huisman H.G., Rensink I., Roem D., Hordijk P.L., et al. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 2001, 167:647-654.
19. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
20. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99:11393-11398.
21. Lee E., Kim Y.S., Bae S.M., Kim S.K., Jin S., Chung S.W., et al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 2009, 15:2755-2765.
22. Nichifor M., Stanciu M.C., Zhu X.X. Bile acids covalently bound to polysaccharides. II. Dextran with pendant cholic acid groups. React Funct Polym 2004, 59:141-148.
23. Nichifor M., Carpov A. Bile acids covalently bound to polysaccharides 1. Esters of bile acids with dextran. Eur Polym J 1999, 35:2125-2129.
24. Park K., Kim J.H., Nam Y.S., Lee S., Nam H.Y., Kim K., et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release 2007, 122:305-314.
25. Ashton A.W., Yokota R., John G., Zhao S., Suadicani S.O., Spray D.C., et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem 1999, 274:35562-43557.
26. Tamilarasan K.P., Kolluru G.K., Rajaram M., Indhumathy M., Saranya R., Chatterjee S. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 2006, 7:17.
27. Achilles E.-G., Fernandez A., Allred E.N., Kisker O., Udagawa T., Beecken W.-D., et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for " no take" of human tumors in mice. J Natl Cancer Inst 2001, 93:1075-1081.
28. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136:261-276.
29. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996, 2:167-168.
30. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
31. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature 2002, 2:420-430.
32. Ziegler U., Groscurth P. Morphological features of cell death. News Physiol Sci 2004, 19:124-128.
33. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
34. Al-Ejeh F., Darby J.M., Brown M.P. Chemotherapy synergizes with radioimmuno-therapy targeting La autoantigen in tumors. PLoS One 2009, 4:e4630.